LBA1: INTerpath-001: Intismeran autogene plus pembrolizumab significantly improves RFS and DMFS in resected stage IIB–IV melanoma

Skin Cancer

Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study

Lancet Oncol

Dummer R, Guo J, Luke JJ, Carlino MS, Schadendorf D, Khattak MA, Hauschild A, Ascierto PA, Chen Y, Shin SJ, Rutkowski P, Luo Z, Chen J, Rivalland G, Coetzee C, Ribas A, Mujika K, Markel G, Villarroel RU, Dizdar O, Caglevic C, Grebennik D, Donovan K, Krepler C, Long GV

doi: 10.1016/S1470-2045(25)00709-0

Skin Cancer

Predictive value of [(18)F]FDG PET/CT and index lymph node response following neoadjuvant pembrolizumab in resectable stage 3 melanoma: Real world data from the largest melanoma centres in the Netherlands

Eur J Cancer

Wilson MJ, Schurink AW, Schrage Y, Wouters MWJM, van Houdt WJ, Grunhagen DJ, van Thienen HV, van de Wiel BA, van der Hiel B, Kuijpers AMJ

doi: 10.1016/j.ejca.2026.116691

SPECIAL REPORT

Gynecologic Cancer

Establishing Pembrolizumab Plus Chemotherapy as a New Standard for dMMR Endometrial Cancer

Skin Cancer

Nivolumab for Resected Stage III or IV Melanoma at 9 Years

N Engl J Med

Ascierto PA, Del Vecchio M, Merelli B, Gogas H, Arance AM, Dalle S, Cowey CL, Schenker M, Gaudy-Marqueste C, Pigozzo J, Márquez-Rodas I, Butler MO, Di Giacomo AM, Gligich O, De La Cruz-Merino L, Arenberger P, Atkinson V, Nathan P, Hill A, Millward M, Fecher LA, Khushalani NI, Queirolo P, Soomro R, Rathod D, Askelson M, Pe Benito M, Joseph D, Larkin J

doi: 10.1056/NEJMoa2504966

CHICAGO 2026

Lung, Respiratory and Thoracic Cancer

LBA4: HARMONi-6: Ivonescimab plus chemotherapy significantly improved OS versus tislelizumab plus chemotherapy in previously untreated advanced squamous NSCLC

ESMO 2026

Lung, Respiratory and Thoracic Cancer

LBA3: DeLLphi-305: Tarlatamab plus durvalumab significantly improves survival as first-line maintenance therapy in ES-SCLC

CHICAGO 2026

Breast Cancer

KEYNOTE-522: Pembrolizumab plus chemotherapy provides sustained EFS and OS benefits at 8-year follow-up in high-risk early-stage TNBC

ESMO 2026

Genitourinary Cancer

LBA2: VOLGA: Perioperative durvalumab plus enfortumab vedotin significantly improves EFS and OS in patients with MIBC

ESMO 2026

Genitourinary Cancer

KEYNOTE-905: Perioperative enfortumab vedotin plus pembrolizumab improves outcomes in cisplatin-ineligible patients with muscle-invasive bladder cancer

Related content

Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study

Predictive value of [(18)F]FDG PET/CT and index lymph node response following neoadjuvant pembrolizumab in resectable stage 3 melanoma: Real world data from the largest melanoma centres in the Netherlands

Establishing Pembrolizumab Plus Chemotherapy as a New Standard for dMMR Endometrial Cancer

Nivolumab for Resected Stage III or IV Melanoma at 9 Years

LBA4: HARMONi-6: Ivonescimab plus chemotherapy significantly improved OS versus tislelizumab plus chemotherapy in previously untreated advanced squamous NSCLC

LBA3: DeLLphi-305: Tarlatamab plus durvalumab significantly improves survival as first-line maintenance therapy in ES-SCLC

KEYNOTE-522: Pembrolizumab plus chemotherapy provides sustained EFS and OS benefits at 8-year follow-up in high-risk early-stage TNBC

LBA2: VOLGA: Perioperative durvalumab plus enfortumab vedotin significantly improves EFS and OS in patients with MIBC

KEYNOTE-905: Perioperative enfortumab vedotin plus pembrolizumab improves outcomes in cisplatin-ineligible patients with muscle-invasive bladder cancer